Norges Bank 89bio, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2024	BUY	$14.15 - $22.03 $2.87 Million - $4.46 Million	202,500 New	202,500 $3.84 Million
Q2 2021 Aug 10, 2021	SELL	$17.42 - $28.0 $858,806 - $1.38 Million	-49,300 Closed	0 $0
Q1 2021 May 09, 2022	BUY	$20.22 - $26.73 $996,846 - $1.32 Million	49,300 New	49,300 $1.17 Million
Q4 2020 Feb 10, 2021	SELL	$23.16 - $28.08 $231,600 - $280,800	-10,000 Closed	0 $0
Q3 2020 Nov 12, 2021	BUY	$24.34 - $38.82 $243,400 - $388,200	10,000 New	10,000 $257,000

166

111M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $508M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.